Boston Scientific completes enrolment for Synergy stent trial

Boston Scientific has completed patient enrolment for Evolve II, a new trial designed to support key regulatory approvals of its Synergy stent system.

The study will assess the safety and effectiveness of the stents in the treatment of atherosclerotic coronary lesions, with 1,684 patients having been recruited at 125 sites worldwide.

Synergy uses the market-leading drug everolimus and features an ultra-thin directional polymer coating that is absorbed by the body shortly after drug elution ends at three months, with previous data from the first Evolve study demonstrating its benefits.

It has already received CE Mark approval in Europe, with Boston Scientific now also looking to launch the product in the US and Japan.

Kevin Ballinger, president of interventional cardiology at Boston Scientific, said: "The Synergy product underscores our ongoing commitment to delivering meaningful innovation to the interventional cardiology community and reinforces our position as a global leader in medical devices."

This comes after the firm also completed patient enrolment for a new study assessing the 12-month safety and effectiveness of its Innova Self-Expanding Stent System last month.